Halo Labs, a Burlingame, Calif.-based life science instrumentation company developing tools for biologics researchers, closed a $12M Series B1 financing round.
The round was led by Research Corporation Technologies with participation from BroadOak Capital Partners, BioAdvance, industry executive Paul McEwan, and other current employees.
The company intends to use the funds for expansion of world-wide Sales presence, the continued development of its next-generation product portfolio, and acquisition of complementary technologies and companies to expand into the analytical particle space.
Led by Robert Wicke, CEO, Halo Labs is a scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation and quality control tools for subvisible particle analysis using custom optics and image processing techniques.
Its Horizon® instrument performs high throughput subvisible particle (SVP) analysis using volumes as low as 25 µL, ensuring samples can be saved for other analyses or for replicates. It has a 96-well membrane plate that allows several parameters to be tested in a short amount of time without dilution or sample preparation.